Interferon-κ, a Novel Type I Interferon Expressed in Human Keratinocytes
David W. Lafleur,Bernardetta Nardelli,Tatiana Tsareva,Don Mather,Ping Feng,Mark Semenuk,Kara Taylor,Markus Buergin,Diana Chinchilla,Viktor Roshke,Guoxian Chen,Steven M. Ruben,Paula M. Pitha,Timothy A. Coleman,Paul A. Moore +14 more
306
TL;DR: Interferon-κ therefore defines a novel subclass of type I interferon that is expressed in keratinocytes and expands the repertoire of known proteins mediating host defense.
read more
About: This article is published in Journal of Biological Chemistry. The article was published on 26 Oct 2001. and is currently open access. The article focuses on the topics: Interferon regulatory factors & Interleukin 29.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.
Sergei V. Kotenko,Grant Gallagher,Vitaliy V. Baurin,Anita Lewis-Antes,Meiling Shen,Nital K. Shah,Jerome A. Langer,Faruk Sheikh,Harold Dickensheets,Raymond P. Donnelly +9 more
TL;DR: The identification of a ligand-receptor system that, upon engagement, leads to the establishment of an antiviral state and may contribute to antiviral or other defenses by a mechanism similar to, but independent of, type I IFNs.
1.8K
Interferons, interferon‐like cytokines, and their receptors
TL;DR: This review summarizes the history of the purification of human IFNs and the key aspects of the current state of knowledge of humanIFN genes, proteins, and receptors and provides some new insights into the development of these proteins as major elements of innate immunity.
1.8K
IL-28, IL-29 and their class II cytokine receptor IL-28R.
Paul O. Sheppard,Wayne R. Kindsvogel,Wenfeng Xu,Katherine E. Henderson,Stacy Schlutsmeyer,Theodore E. Whitmore,Rolf E. Kuestner,Ursula Garrigues,Carl W. Birks,Jenny Roraback,Craig D. Ostrander,Dennis L. Dong,Jinu Shin,Scott R. Presnell,Brian A. Fox,Betty A. Haldeman,Emily Cooper,David W. Taft,Teresa Gilbert,Francis J. Grant,Tackett Monica L,William Krivan,Gary L. McKnight,Chris Clegg,Don Foster,Kevin M. Klucher +25 more
TL;DR: A family of three cytokines, designated interleukin 28A, IL-28B and IL-29, that are distantly related to type I interferons (IFNs) and the IL-10 family are identified and may serve as an alternative totype I IFNs in providing immunity to viral infection.
1.7K
Interferons at age 50: past, current and future impact on biomedicine.
Ernest C. Borden,Ganes C. Sen,Gilles Uzé,Robert H. Silverman,Richard M. Ransohoff,Graham R. Foster,George Stark Stark +6 more
TL;DR: The goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.
1.2K
Interleukin-10 and Related Cytokines and Receptors
Sidney Pestka,Christopher D. Krause,Devanand Sarkar,Mark R. Walter,Yufang Shi,Paul B. Fisher +5 more
TL;DR: These cytokines have significant roles in a variety of pathophysiological processes as well as in regulation of the immune system and further investigation of these critical intercellular signaling molecules will provide important information to enable these proteins to be used more extensively in therapy for a range of diseases.
1.2K
References
Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo
John W. Greiner,Fiorella Guadagni,Philip D. Noguchi,Sidney Pestka,David Colcher,Paul B. Fisher,Jeffrey Schlom +6 more
TL;DR: Concomitant administration of Hu-IFN-alpha A and monoclonal antibody may be effective in overcoming the antigenic heterogeneity of carcinoma cell populations and in enhancing the efficacy of monocolonal antibodies in the detection and treatment of carcinomas lesions.
Related Papers (5)
[...]